RedHill gets U.S. patent application allowances for opaganib and RHB-107 in COVID-19
May 26, 2021 8:16 AM ETRedHill Biopharma Ltd. (RDHL)RedHill Biopharma Ltd. (RDHL)By: Aakash Babu, SA News Editor
RedHill Biopharma (NASDAQ:RDHL) announces the receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib and RHB-107 (upamostat) as methods for the treatment of COVID-19.
Both opaganib and RHB-107 are novel COVID-19 therapeutic candidates, in oral pill form, with dual mechanism of action effects.
The new intellectual property protection extends until at least 2041, the company said.
Shares up nearly 5% premarket.
The independent Data Safety Monitoring Board (DSMB) had unanimously recommended to continue the study of RedHill's Phase 2/3 study with orally-administered opaganib in patients hospitalized with severe COVID-19, following a fourth safety review, last month.
News 
Market Data 
Discover 
